Cystic Fibrosis News Digest — Issue 04

Jasmin Berger, Yin Yu, Julian Berges, et al.

Summary: This prospective multicenter study used intestinal current measurements (ICM) on rectal biopsies to quantify CFTR function in 26 children aged 2–11 years with at least one F508del allele, before and four months after starting elexacaftor/tezacaftor/ivacaftor (ETI). ETI restored cAMP-induced chloride secretion to a median of approximately 89.5% and total chloride secretory response to approximately 99.2% of non-CF control values — substantially higher than the approximately 40% restoration previously documented in adolescents and adults. A strong inverse correlation with age (R² = 0.43–0.53) suggests that younger patients achieve greater functional correction.

Why it matters: The finding that ETI can restore CFTR function to near-normal levels in young children is biologically and clinically significant. If confirmed and sustained, it raises the possibility that early ETI initiation could prevent, rather than merely slow, the organ damage that accumulates before adolescence in CF. The age-dependent correlation also generates a testable hypothesis — that earlier treatment yields greater functional benefit — with direct implications for newborn screening programs and treatment initiation guidelines.

Expert perspective: The study's strengths include its prospective design, use of ICM (a well-validated and sensitive functional biomarker measured directly in rectal tissue), and a head-to-head comparison with a prior adult cohort using the same methodology. These features make the between-age-group comparison more credible than typical cross-study comparisons. That said, the sample size of 26 children is small, and the IQR for functional restoration is wide (51–144% for total chloride response), indicating substantial inter-individual variability — some children achieved far less than near-normal correction. The four-month follow-up is too short to draw conclusions about clinical outcomes such as lung function trajectory, exacerbation rates, or structural lung changes. Whether near-normal CFTR function at the cellular level translates into disease prevention at the organ level remains unproven. The correlation between age and CFTR correction is intriguing but must be interpreted cautiously: it is cross-sectional within the pediatric cohort, and confounding by genotype, disease severity, or residual CFTR function cannot be excluded in this modest sample. Longer-term registry-based or controlled studies linking functional biomarker restoration to hard clinical endpoints — particularly in the 2–5 year age group now eligible for ETI — are the logical and necessary next step. This is a genuinely important mechanistic finding, but near-normal ion transport is not the same as a cure; it is, however, a more encouraging starting point than many in the field anticipated.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42785803/

---

Cynthia D Brown, Kevin J Psoter, Kathryn A Sabadosa, et al.

Summary: The HERO-2 study is a 12-month prospective observational study of 709 people with CF (age ≥12) taking elexacaftor/tezacaftor/ivacaftor (ETI), examining whether self-reported discontinuation of one or more chronic daily therapies (CDTs) is associated with worse pulmonary outcomes. Using inverse probability weighting to adjust for baseline differences, the study found no statistically significant association between CDT discontinuation and increased pulmonary exacerbations or lung function decline over 12 months. Notably, 41.5% of participants reported having discontinued at least one CDT at baseline, underscoring how common this practice already is in the real world.

Why it matters: As ETI has dramatically improved symptoms and lung function for many people with CF, patients and clinicians are naturally questioning whether the full burden of chronic airway clearance, inhaled antibiotics, mucolytics, and other therapies remains necessary. This study provides the first prospective observational data on outcomes associated with CDT discontinuation in the ETI era, directly addressing a question that registries and cross-sectional surveys cannot answer well. The finding that de-escalation was not detectably harmful over 12 months is clinically meaningful and may help inform shared decision-making conversations, even if it cannot definitively endorse discontinuation.

Expert perspective: The study is methodologically thoughtful for real-world research: prospective design, registry-linked outcomes, remote enrollment broadening geographic reach, and inverse probability weighting to address confounding. However, several limitations deserve careful attention. CDT discontinuation was self-reported at baseline through a patient-facing app, meaning the specific therapies discontinued, the timing, and adherence patterns are incompletely characterized. Twelve months may be insufficient to detect slow lung function trajectories or infrequent exacerbations in a relatively well population on ETI. Selection bias is a genuine concern: patients who feel well enough to stop therapies may differ systematically from those who do not, and inverse probability weighting adjusts only for measured confounders. The study population is self-selected through a remote app-based platform, which may over-represent engaged, health-literate patients with milder disease or stronger disease control on ETI. The confidence intervals around both primary outcomes, while including zero, are wide enough that clinically meaningful harms cannot be excluded. This study does not establish safety of CDT discontinuation; it establishes that in this sample, over this timeframe, no detectable harm was observed. That is a meaningful and useful finding, but it should be communicated with appropriate nuance. Longer follow-up, better characterization of which CDTs are stopped, and more diverse enrollment are needed before de-escalation can be broadly recommended.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42554296/

---

Hande Yetişgin, Işıl Bilgiç, Meltem Kürtül Çakar, et al.

Summary: This prospective observational study from Turkey followed 24 children with cystic fibrosis receiving CFTR modulator therapy and their parents over 18 months, measuring mental health, sleep quality, and quality of life at baseline and follow-up. Statistically significant improvements were observed in child anxiety, depression, and daytime sleepiness scores, as well as in parental depression, anxiety, caregiver burden, and overall quality of life. CFQ-R scores improved in physical, social, and respiratory domains for both patients and parent proxies.

Why it matters: The psychological burden of CF on patients and families is substantial and historically underappreciated relative to pulmonary outcomes. If CFTR modulators — already known to improve lung function and nutritional status — also meaningfully reduce anxiety, depression, and caregiver burden, the case for early and sustained access to these therapies becomes even stronger. This study adds longitudinal data to a literature dominated by cross-sectional observations, which is a meaningful methodological step forward, even if the sample is small.

Expert perspective: The findings are directionally plausible and clinically interesting, but several limitations prevent strong causal conclusions. Most fundamentally, the study lacks a control group. With only 24 participants — drawn from a single center in Turkey and representing a continuation of a prior cross-sectional study — it is impossible to distinguish the effects of modulator therapy from natural disease trajectory, regression to the mean, the passage of time, or the psychosocial benefits of being enrolled in an attentive clinical study. The 18-month follow-up is a genuine strength relative to most prior work, and the use of validated instruments (CDI, SCARED, BDI, BAI, ZBI, WHOQOL-BREF, CFQ-R) is appropriate. However, statistical significance across multiple endpoints in a sample this small warrants caution; with n=24, the study is underpowered to reliably estimate effect sizes, and multiple comparisons increase the risk of spurious findings. Eighteen months of modulator therapy inevitably produces respiratory and nutritional improvements, making it exceedingly difficult to isolate a direct psychosocial effect of the drug from indirect benefits mediated through better physical health. The generalizability of findings to populations with different modulator access patterns, healthcare contexts, or CF mutation distributions is uncertain. Despite these limitations, this is a useful piece of incremental evidence suggesting that the benefits of CFTR modulators likely extend beyond forced expiratory volume. Larger, controlled, multicenter studies — ideally incorporating diverse CF populations and stratifying by modulator type — are needed before firm conclusions can be drawn.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42576010/

---

Hiba J Mustafa, Yair J Blumenfeld, Ramen H Chmait, et al.

Summary: This review synthesizes current evidence on prenatal exposure to CFTR modulator therapies — primarily elexacaftor/tezacaftor/ivacaftor (ETI) and the newer vanzacaftor/tezacaftor/deutivacaftor (VTD) — in pregnancies affected by cystic fibrosis, both for maternal benefit and as a potential directed fetal therapy. Key findings include placental transfer of both agents at pharmacologically relevant fetal concentrations, apparent stabilization of maternal pulmonary and nutritional status, and case-series evidence of resolution or improvement of fetal bowel abnormalities consistent with meconium ileus. The review also highlights unresolved questions around timing, fetal pharmacokinetics, long-term neurodevelopmental outcomes, and the risk of falsely negative newborn screening.

Why it matters: CF organ damage begins in utero — meconium ileus, pancreatic insufficiency, and reproductive tract anomalies are present at birth — so the prospect of a first true fetal therapy for CF is scientifically and clinically significant. The transformation of CF prognosis by modulators has also produced a substantial increase in pregnancies among people with CF, making the maternal-continuation question immediately practical for large numbers of clinicians and patients. If intentional prenatal therapy can reliably prevent meconium ileus and preserve pancreatic or reproductive function, the implications for morbidity and quality of life would be meaningful, though this remains to be established rigorously.

Expert perspective: The evidence base here is genuinely early-stage and must be read accordingly. The body of data consists of observational cohorts, case series, pharmacokinetic studies, animal models, and expert consensus — not randomized controlled trials, which are difficult to design and execute in pregnancy. Selection bias is a substantial concern: women continuing ETI during pregnancy are likely to be healthier and more closely monitored than those who discontinue, and individual fetal cases reported in series are unlikely to be representative. The cataract signal, though described as clinically minor so far, has not been systematically evaluated across large cohorts, and the mechanism is not fully understood; it warrants continued structured surveillance. The newborn screening problem — falsely negative results following prenatal modulator exposure — is an immediately actionable, underappreciated public-health issue that deserves explicit clinical protocols now, regardless of broader questions about fetal indication. The authors are appropriately cautious in labeling fetal-indication use as investigational, and the call for interdisciplinary coordination and the PROTECT Workshop framework reflects a responsible approach. The field needs prospective registries with standardized outcome definitions, long-term neurodevelopmental follow-up, and ideally some form of controlled comparative design, even if conventional randomization is not feasible. The gap between the biological rationale and the evidence needed to guide routine fetal-indication prescribing remains wide.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42819752/

---

Diane A Merino, Samuel D Cohen, Nouha Ben Othman, et al.

Summary: This study analyzed spontaneous adverse-event reports from the French Pharmacovigilance Database (116 cases) and VigiBase (3,407 cases) to characterize psychiatric adverse events associated with CFTR modulators (CFTRms), primarily elexacaftor/tezacaftor/ivacaftor (ETI), reported between 2012 and 2024. Sleep disorders predominated in children, while mood and suicidality-related reports were more common in adolescents. Disproportionality analysis using Reporting Odds Ratio showed that mental health disorders were over-represented with CFTRms — particularly ETI — compared with other drugs in VigiBase, with signals somewhat stronger in pediatric patients. Completed suicides were not reported; six suicide attempts were identified in the French database.

Why it matters: ETI has dramatically improved lung function and survival in CF, but its near-universal uptake means that even rare adverse effects carry population-level importance. Mental health concerns have been raised anecdotally and in earlier case series; this analysis is among the more systematic pharmacovigilance efforts to date and adds age-stratified signal detection. If a genuine causal relationship exists, it has direct implications for monitoring protocols, prescribing guidance, and patient and family counseling — especially in pediatric populations where neurodevelopmental vulnerability may amplify risk.

Expert perspective: The methodology is appropriate for pharmacovigilance hypothesis generation: disproportionality analysis using ROR is a recognized signal-detection tool, and adherence to STROBE and READUS-PV guidelines is a positive indicator of rigor. However, the fundamental limitations of spontaneous reporting databases must be kept in view. These systems are subject to notoriety bias — clinicians are more likely to report psychiatric events for a drug already under scrutiny — as well as underreporting of routine events, absence of a true denominator, and complete inability to adjust for confounders, including the well-documented burden of anxiety and depression intrinsic to living with CF. The dramatic improvement in physical health that ETI produces may itself unmask pre-existing psychological distress, alter sleep architecture, or shift patients' attention toward previously suppressed mental health symptoms. The signal with ETI but not other combination therapies is intriguing, though the comparison is complicated by vastly different numbers of exposed patients and reporting periods. The pediatric-versus-adult stratification adds value, but sample sizes in subgroups limit precision. The median time to onset of 60 days is clinically useful if confirmed prospectively. Reassuringly, completed suicides were absent and suicidal behavior was infrequent overall. This is useful hypothesis-generating evidence that appropriately calls for prospective, controlled observational studies with validated psychiatric endpoints, baseline assessments, and CF-specific comparator populations — not a reason to alter prescribing, but a reasonable basis for structured clinical monitoring.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42707002/

---

Jonathan H Rayment, Gwyneth Davies, Jonathan M Gaffin, et al.

Summary: The TIMBERLINE phase 3 open-label study evaluated vanzacaftor-tezacaftor-deutivacaftor (vanza-teza-deuti) in 67 children aged 2–5 years with ETI-responsive genotypes over 24 weeks. The primary endpoint of safety and tolerability was met, with no treatment-related serious adverse events and no discontinuations. Transitioning from elexacaftor-tezacaftor-ivacaftor (ETI), children achieved a further mean sweat chloride reduction of 9.6 mmol/L, with 65% reaching concentrations below 30 mmol/L.

Why it matters: Extending effective CFTR modulation to preschool-aged children is clinically meaningful because early intervention may limit cumulative lung damage and systemic complications that accrue before school age. Vanza-teza-deuti has already demonstrated superiority over ETI in older cohorts, and these findings suggest the incremental benefit extends to the youngest treatable patients. Given the rarity of this population and the practical challenges of conducting trials in toddlers, this dataset — though small — represents a meaningful advance in the regulatory pathway for label expansion.

Expert perspective: The study is appropriately designed for its developmental stage: a single-arm, open-label phase 3 trial is a defensible and pragmatic choice in a small pediatric population where placebo-controlled designs raise ethical and logistical barriers. The 100% completion rate across 67 children is reassuring, though the open-label design and short 24-week follow-up limit conclusions about long-term safety and functional pulmonary outcomes — spirometry is not reliably measurable in this age group. Using ETI as the active baseline rather than placebo is methodologically sensible but means the incremental benefit of approximately 9.6 mmol/L sweat chloride reduction is measured against an already highly effective therapy, making absolute effect size modest. The 65% achieving sweat chloride below 30 mmol/L is clinically notable, though the long-term significance of this threshold in preschoolers remains incompletely characterized. Vertex funding warrants standard scrutiny, though the trial registration, multicenter design across nine countries, and publication in Lancet Respiratory Medicine provide reasonable confidence in data integrity. Longer follow-up and functional endpoints remain the critical next step.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42710511/

---